TetraGraph Exhibition and Poster presentation at The Euroanaesthesia 2018 Annual Meeting, Copenhagen, Denmark, June 2-4

Euroanaesthesia is Europe’s largest annual event showcasing the latest and the most relevant knowledge with medical experts active in the field of anaesthesia, perioperative medicine, intensive care, emergency medicine and pain treatment. This international event gathers around 6000 of delegates and exhibitors from over 80 countries.

TetraGraph is a unique, electromyography-based portable device designed for quantitative monitoring of neuromuscular function. It is an easy to use tool for precise monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician reduce the incidence of residual block. Senzime held demonstrations of the TetraGraph during the conference which generated great interest from clinicians to learn more about its benefits and possibilities.

During the meeting, Reka Nemes, MD, Mayo Clinic, Jacksonville, Florida presented a poster entitled, “Assessment of the variability of electromyography and acceleromyography derived train-of-four ratios and the discomfort associated with neurostimulation in unmedicated volunteers: an international observational study”. 

The poster concluded that the electromyography-based TetraGraph had higher precision and caused similar level of discomfort in unmedicated volunteers than the acceleromyography-based TOF-Watch S neuromuscular monitor.

For further information, please contact:

Lena Söderström, CEO   

Tel: +46-708-16 39 12                                         

Lena.soderstrom@senzime.com                     

Catrin Molund, Marketing & Business Development Director

Tel: +46-708-11 69 11

Catrin.molund@senzime.com 

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease healthcare costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com